FindTrial
Sign In

A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.

A study of R435 (Bevacizumab) in Combination With R340 (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220416
Enrollment
Unknown
Registered
2007-07-17
Start date
2007-07-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusin criteria: - adult patients, >=18 years of age - inoperable, locally advanced or metastatic cancer of stomach or gastro-esophageal junction - measurable or non-measurable but evaluable disease - ECOG PS of 0, 1 or 2 Exclusion criteria: - previous chemotherapy for locally advanced or metastatic gastric cancer - previous platinum or anti-angiogenic therapy - patients with locally advanced disease who are candidates for curative therapy - radiotherapy within 28 days of randomisation - evidence of CNS metastasis - inadequate organ function - history of bleeding or wound-healing complications

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Overall survival—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026